Guanfacine: Indications, Dosing, Monitoring, and Adverse Effects
Indications
Guanfacine has two distinct FDA-approved indications depending on formulation: immediate-release for hypertension in adults, and extended-release for ADHD in children and adolescents. 1
- Immediate-release (IR): Treatment of hypertension, typically as monotherapy or in combination with other antihypertensives
- Extended-release (ER/GXR): Treatment of ADHD in patients aged 6-17 years 2, 3
The 2025 AHA/ACC hypertension guidelines specifically recommend considering nonstimulant medications like guanfacine for ADHD patients when stimulants need to be discontinued or reduced due to blood pressure concerns 4.
Dosing Regimens
For Hypertension (Immediate-Release)
Start with 1 mg daily at bedtime to minimize somnolence; if inadequate response after 3-4 weeks, may increase to 2 mg daily. 1
- Initial dose: 1 mg at bedtime
- Maintenance: 1-2 mg daily (most effect seen at 1 mg)
- Maximum: 3 mg/day (doses above 3 mg significantly increase adverse reactions)
- Timing: Bedtime dosing preferred to minimize daytime sedation
- Duration to effect: 3-4 weeks for full assessment 1
For ADHD (Extended-Release)
For children and adolescents, initiate at 1 mg daily and titrate weekly by 1 mg increments based on clinical response and tolerability, targeting weight-adjusted doses of 0.05-0.12 mg/kg/day. 5, 3
- Children 6-12 years: 1-4 mg/day
- Adolescents 13-17 years: 1-7 mg/day (up to 9 mg studied in research settings) 5
- Adults: 2 mg starting dose, maintenance 4-6 mg/day 6
- Titration: Weekly increases of 1 mg as tolerated
- Optimal dosing: Weight-adjusted doses >0.08 mg/kg but ≤0.12 mg/kg may provide additional clinical benefits 5
Critical formulation warning: IR and ER formulations are NOT interchangeable. A case report documented severe bradycardia and hypotension requiring PICU admission when a 6-year-old received IR instead of ER formulation 7.
Mechanism and Pharmacokinetics
Guanfacine is a selective α2A-adrenergic agonist that reduces sympathetic outflow from the CNS, decreasing peripheral vascular resistance and heart rate 1.
Key pharmacokinetic parameters:
- Bioavailability: ~80%
- Time to peak: 1-4 hours (average 2.6 hours)
- Half-life: 17 hours (range 10-30 hours; shorter in younger patients at 13-14 hours)
- Steady state: Achieved within 4 days
- Excretion: 50% unchanged in urine, 50% as metabolites 1
Monitoring Parameters
Cardiovascular Monitoring (Essential for Both Indications)
Monitor blood pressure and heart rate at baseline, after each dose increase, and regularly during maintenance therapy. 8, 5
- Blood pressure: Sitting and standing measurements (guanfacine blunts the physiologic BP increase upon standing in a dose-dependent manner) 5
- Heart rate: Expect average decrease of 5 bpm; monitor for clinically significant bradycardia 1, 8
- ECG: Consider baseline and follow-up ECG, particularly in patients with cardiac risk factors
ADHD-Specific Monitoring
- ADHD-RS-IV scores: Assess symptom improvement 3
- CGI-I and PGI-I scales: Global improvement assessment 3, 6
- Functional impairment: School/learning and family functioning 3
Renal Function
Monitor in patients with renal impairment, as 50% is excreted unchanged renally 1.
Adverse Effects
Most Common Treatment-Emergent Adverse Events
Approximately 80% of patients on guanfacine experience at least one adverse event, compared to 66.5% on placebo, with most being mild to moderate in severity. 2
Top adverse effects by frequency:
- Somnolence: 38.6% (most common, dose-dependent) 2, 3
- Headache: 20.5% 2
- Fatigue: 15.2% 2
- Dry mouth 9
- Constipation 9
- Dizziness/postural dizziness 5, 6
- Thirst 6
Cardiovascular Effects
- Bradycardia: Dose-dependent; can be severe enough to require discontinuation 8, 7
- Hypotension: Dose-dependent decreases in BP; blunted orthostatic response 5, 7
- Sinus bradycardia: Common TEAE 5
Serious Considerations
- Discontinuation rate: In ADHD trials, guanfacine showed dose-dependent discontinuation risk up to 4 mg/day, reaching 9.8% (95% CrI 4.4-20%) 10
- Formulation errors: Can cause profound hemodynamic instability requiring intensive care 7
Withdrawal Effects
Guanfacine has a lower risk of rebound hypertension compared to clonidine, with delayed onset (2-4 days) and gradual return to baseline pressures. 1
- Rebound occurs 2-4 days after discontinuation (vs. immediate with clonidine)
- Blood pressure typically returns to pretreatment levels slowly over 2-4 days
- Avoid abrupt discontinuation; taper when possible 1
Clinical Pearls and Pitfalls
Critical Warnings
- Never substitute IR for ER formulations - this can cause life-threatening bradycardia and hypotension 7
- Bedtime dosing for hypertension reduces daytime somnolence 1
- Doses above 3 mg/day for hypertension significantly increase adverse reactions without proportional benefit 1
- Monitor orthostatic vital signs - the physiologic BP increase upon standing is blunted dose-dependently 5
Efficacy Considerations
- For hypertension: Most effect seen at 1 mg; 24-hour coverage documented 1
- For ADHD: Significant improvements in ADHD-RS-IV scores (placebo-adjusted difference -8.9, p<0.001) 3
- ADHD functional improvements: Learning/school domain and family domain show significant benefits 3
- Long-term ADHD treatment (50 weeks) shows sustained efficacy with acceptable safety profile 6
Population-Specific Notes
- White patients: May respond to 1 mg for hypertension 1
- Black patients: Generally require 2 mg or higher for hypertension 1
- Younger patients: Shorter half-life (13-14 hours) 1
- Older patients: Half-life at upper end of range (up to 30 hours) 1
- Weight >70-90 kg adolescents: Lower clearance at steady state 5